Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of December 2, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
马萨诸塞州沃尔瑟姆,2024年12月6日(环球新闻稿)—— Apellis Pharmaceuticals, Inc. (纳斯达克: APLS),一家全球生物制药公司和补体领域的领导者,今天宣布公司批准向四名新员工授予股权奖励,授予日期为2024年12月2日,作为公司2017年股票激励计划之外的股权诱导奖励(但根据2020年诱导股票激励计划的条款),这些对员工接受公司的就业至关重要。该股权奖励的批准是根据纳斯达克上市规则5635(c)(4)进行的。
The employees received options to purchase 27,445 shares of Apellis' common stock and 28,630 restricted stock units (RSUs). The options have an exercise price of $35.42, which is equal to the closing price of Apellis' common stock on December 2, 2024, the grant date of the options. One-fourth of the shares underlying the employee options will vest on the one-year anniversary of the grant date and thereafter 1/48th of the shares underlying the employee options will vest monthly, such that the shares underlying the options granted to the employees will be fully vested on the fourth anniversary of the grant date, subject to the employees' continued employment with Apellis on such vesting dates. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date.
员工获得购买27,445股Apellis普通股的期权和28,630个限制性股票单位(RSU)。期权的行使价格为35.42美元,与2024年12月2日,期权的授予日期,Apellis普通股的收盘价格相等。员工期权所对应的四分之一股票将在授予日期的一周年纪念日时归属,此后员工期权所对应的股票将每月归属1/48的股份,从而员工授予的期权所对应的股票将在授予日期的第四个周年时完全归属,前提是员工在这些归属日期继续留在Apellis工作。每个RSU将在授予日期的一周年时归属所对应股份的25%,此后每年再归属所对应股份的额外25%,前提是每名员工在每个归属日期继续留任。
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit or follow us on Twitter and LinkedIn.
关于Apellis
Apellis Pharmaceuticals, Inc.是一家全球生物制药公司,结合勇敢的科学与同情心,为患者所面临的某些最具挑战性的疾病开发改变生命的疗法。我们引入了15年来首个新类别的补体药物,目前已有两种针对C3的获批药物。这些药物包括全球失明主要原因——地理性萎缩的首个治疗方案。我们相信,我们才刚刚开始解锁针对C3在严重眼底疾病、罕见病和神经疾病中的潜力。欲了解更多信息,请访问或在Twitter和LinkedIn上关注我们。
Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding plans to submit applications for regulatory approval for the treatment of patients with C3G and IC-MPGN. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether systemic pegcetacoplan will receive approval for those indications from the FDA or equivalent foreign regulatory agencies when expected or at all; and any other factors discussed in the "Risk Factors" section of Apellis' Annual Report on Form 10-K with the Securities and Exchange Commission on February 27, 2024 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Apellis前瞻性声明
本新闻稿中关于未来期望、计划和前景的声明,以及任何其他涉及非历史事实的事项的声明,可能构成1995年《私人证券诉讼改革法》的意义下的“前瞻性声明”。这些声明包括但不限于关于提交申请以获得对C3G和IC-MPGN患者治疗的监管批准的计划的声明。词语“预期”、“相信”、“继续”、“可能”、“估计”、“期待”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将要”、“会”和类似的表达,旨在识别前瞻性声明,尽管并非所有前瞻性声明都包含这些识别词。由于各种重要因素,实际结果可能与这些前瞻性声明所示的结果存在实质性差异,包括系统性pegcetacoplan是否能按预期或根本不获得FDA或等同外国监管机构对这些指示的批准;以及在Apellis于2024年2月27日向证券交易委员会提交的10-k年报的“风险因素”部分讨论的其他因素和Apellis可能向证券交易委员会提交的其他文件中描述的风险。本新闻稿中包含的任何前瞻性声明仅在本文日期生效,Apellis明确声明不承担更新任何前瞻性声明的义务,无论是因为新信息、未来事件还是其他原因。
Media Contact:
Tracy Vineis
media@apellis.com
617-420-4839
媒体联系人:
特雷西·维内斯
media@apellis.com
617-420-4839
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
投资者联系人:
梅雷迪斯·卡雅
meredith.kaya@apellis.com
617.599.8178